DRI Healthcare agrees $316 million purchase of tavapadon royalties
DRI Healthcare Trust said it entered purchase agreements to buy certain royalty participation rights tied to U.S. net sales of tavapadon, an investigational Parkinson’s disease drug candidate.
S. net sales of tavapadon, an investigational Parkinson's disease drug candidate. The Toronto-based pharmaceutical royalty company said Monday it entered into purchase agreements to acquire the rights.